• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>European Journal of Haematology >The efficacy and safety of modified bortezomib‐lenalidomide‐dexamethasone in transplant‐eligible patients with newly diagnosed multiple myeloma
【24h】

The efficacy and safety of modified bortezomib‐lenalidomide‐dexamethasone in transplant‐eligible patients with newly diagnosed multiple myeloma

机译：改性硼替佐米 - Lenalidomide-DexameLasone在移植型肌瘤移植患者中的疗效和安全性

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Abstract Objectives Bortezomib with lenalidomide and dexamethasone (VRd) is a standard induction regimen for transplant‐eligible patients with newly diagnosed multiple myeloma (NDMM). However, some patients discontinue VRd because of severe adverse events, despite its high efficacy. We aimed to study the efficacy of modified dose of VRd (VRd lite) in transplant‐eligible patients with NDMM. Methods Forty‐eight transplant‐eligible patients with NDMM were included. VRd lite was administered every 4?weeks. Bortezomib 1.3?mg/m 2 was administered subcutaneously on days 1, 8, 15 and 22, and dexamethasone 20?mg was administered orally on the day of and the day after bortezomib administration. Lenalidomide was omitted on days 1, 8 and 15, which are the days of bortezomib administration. Results The overall response rate (ORR) after four cycles of VRd lite was 83%, including a complete response of 25%. Thirty‐eight among the 45 patients who completed at least four cycles of VRd lite received autologous stem cell transplantation (ASCT). The ORR and very good partial response or better were upgraded to 100% and 74%, respectively, following ASCT. Conclusion Our strategy consisting of VRd lite followed by ASCT is, thus, a highly effective and well‐tolerated regimen resulting in durable responses in patients with NDMM.
机译：摘要目标硼二氮杂胺和邻塞米松（VRD）是一种标准的移植符合条件患者新诊断的多发性骨髓瘤（NDMM）的诱导方案。然而，尽管其疗效高，但有些患者因严重不良事件而停止VRD。我们的旨在研究改性剂量的VRD（VRD Lite）在移植符合条件的NDMM患者中的疗效。方法包括四十八种符合人权NDMM患者。 vrd lite每4个？几周给药。硼替佐米1.3？Mg / m 2皮下给药在第1,8,15和22天，并且在硼佐米布施用后的日期和第二天口服施用地塞米松20μg。在第1,8和15天省略了Lenalidomide，这是硼替佐米给药的日子。结果VRD Lite四个周期后的总回应率（ORR）为83％，包括25％的完整响应。在45名患者中完成至少四个VRD Lite的患者中的38个患者接受了自体干细胞移植（ASCT）。 ORR和非常好的部分响应或更好分别升级至100％和74％，后面依赖于ASCT。结论我们由VRD Lite组成的策略，然后是ASCT的高效且耐受良好的方案，导致NDMM患者的耐用反应。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号